Neuromuscular Disease Network for Canada (NMD4C)

We provide opportunities for professional development, education, virtual discussions, networking, and the sharing of data and resources. N4 is a national network for the diversity of providers who assist newcomers in navigating the complex Canadian healthcare and social service systems. From 2019 – 2022, N4 successfully built a robust network of professionals from diverse sectors and geographies passionate about advancing health equity and improving their services to meet the needs of those newest to Canada. Each month, N4 provides a visual data snapshot of key quantitative data sets in a simple and useable formats.

We are more than 40 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. At NMD Pharma, we are passionate about movement. We are passionate about turning science into novel therapeutics that enable patients with neuromuscular diseases to live more independent lives. We are creative and innovative in our discovery of novel therapeutics by encouraging free thinking and knowledge sharing. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence. We are working to develop novel small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that can be applied to a large range of clinical indications and orphan human diseases. NMD Pharma is a clinical-stage biotech company founded with a focus to deliver life-transforming therapies for people living with neuromuscular diseases.

Our mission is to generate interest and support from the Canadian public about NTDs, and advocate for the elimination of NTDs to be a key part of Canada’s global health priorities. The Canadian Network for NTDs is a network of interested Canadian individuals and organizations who aim to mobilize Canadian action to end suffering from NTDs. Our network of global health practitioners and researchers provide world-class insight and support for Canadian policy on NTDs. We believe that addressing NTDs is the missing piece to improved global health. Tina has an MSc in Global Public Health & more than 10 years of experience in international development; having worked in project development for health and education projects primarily for countries in Africa, working with Plan Canada, IOM (International Organization for Migration), Canadian Feed the Children & IDRF (International Development & Relief Fund). Deborah is a third year health sciences student from the University of Calgary. The Canadian Network for NTDs is a vibrant network of interested Canadian individuals and organizations who mobilize Canadian action to end suffering from NTDs.

We are a national partnership of patients, researchers, health care providers, and policy-makers working to transform treatment and care for Canadians affected by chronic kidney disease. We are changing the culture of kidney research by involving patients throughout the research process. We are one of five chronic disease networks supported by the Canadian Institutes of Health Research through Canada’s Strategy for Patient-Oriented Research (SPOR). We are advancing equity in health research through our core values. We are proud to partner with more than 60 organizations. We are a Canada-wide network of patients, scientists, and health care professionals creating innovative kidney care solutions. Our network coordinates and conducts innovative research using a patient-oriented approach. We also create resources and tools that enhance Canada’s ability to lead innovative kidney health research.

The CDCN will host our signature fundraising event on May 9, 2024 at Appleford in Villanova, PA. The CDCN team is incredibly focused on finding what works and quickly discarding what doesn’t. The Castleman Disease Collaborative Network (CDCN) is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The Castleman Disease Collaborative Network (CDCN) is dedicated to accelerating research and treatment for Castleman disease, supporting patients on their journeys, and revolutionizing biomedical research for countless other diseases. It’s an approach that has pulled together a network of experts from across the globe. When the co-founder is a patient and the disease can be deadly, there is no time to waste. Castleman disease is a journey for patients and all those they love that begins with a difficult diagnosis followed by finding a specialist, choosing a treatment, recovering, and surviving.

The devastating impact of COVID-19 on the general population is well-documented—but less is known about the millions of people living with rare diseases. Our network, now in its fourth five-year funding cycle, is a partnership with funding and programmatic support provided by Institutes, Centers and Offices across NIH.